MassHealth Drug Utilization Review (DUR) Program

(800) 745-7318 (phone)

(877) 208-7428 (fax)

DUR BOARD MEETING (REMOTE)

Quarterly Meeting

June 12, 2024

AGENDA

1. Welcome and Introductory Remarks

1. Resident Research Project: An Evaluation of Hospitalizations and Healthcare Costs in Medicaid Patients with Insulin-Dependent Type 2 Diabetes Mellitus Monitored with Continuous Glucose Monitoring Devices versus Capillary Blood Glucose Monitoring

This is an overview of a research project developed by current managed care pharmacy residents.

1. Antipsychotics Agents Quality Assurance Analysis

This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state.

1. Antiretroviral Agents Quality Assurance Analysis

This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state.

1. MHDL Update

MHDL Overview including new additions, changes in Prior Authorization (PA) status, and related attachment updates to be implemented with a recent publication rollout.

1. DUR Operational Update

DUR Operational Overview including statistics associated with Prior Authorization (PA) review and PA response, and Call Center metrics

1. MassHealth Update

MassHealth Update is a brief summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.

1. Oncology Immunotherapies Quality Assurance Analysis *(time permitting)*

This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state.

1. Open Forum

*Zoom link: https://umassmed.zoom.us/j/94100445136?pwd=WWlTbjFWQ3pZck92aFhqN2czVjhGdz09*

*Time: 6:00pm – 8:00pm*

*The Massachusetts Commission for the Deaf and Hard of Hearing will assist with arrangements for a sign language interpreter. The Commission may be reached at 617-740-1600 VOICE and 617-740-1700 TTY.*

***Next DUR Board (open meeting): September 11, 2024***